Amerisource Health Services Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Amerisource Health Services Pharmaceutical Import Records from India — 8 Products, $8.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amerisource Health Services — Pharmaceutical Importer Profile (2026) | 8 Products, $8.9M Trade | TransData Nexus

Amerisource Health Services

Pharmaceutical Importer · United States · Cardiovascular Focus · $8.9M Total Trade · DGFT Verified

Amerisource Health Services is a pharmaceutical importer based in United States with a total trade value of $8.9M across 8 products in 6 therapeutic categories. Based on 282 verified import shipments from Indian Customs (DGFT) records, Amerisource Health Services is the #1 buyer in 1 product including Montelukast. Amerisource Health Services sources from 19 verified Indian suppliers, with Glenmark Pharmaceuticals Limited accounting for 28.6% of imports.

Amerisource Health Services — Import Portfolio & Supplier Network

Amerisource Health Services import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Amerisource Health Services?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$12.8M	374	28.6%
Zydus Lifesciences Limited	$7.1M	336	15.8%
Lupin Limited

What Formulations Does Amerisource Health Services Import?

Formulation	Value	Ships
Pharmaceutical medicine for human	$1.0M	30
Pharmaceuticals- gabapentin TAB 600MG	$900.0K	18
Pharmaceuticals- gabapentin TAB 600MG 500 (BP)	$767.6K	16
Pharmaceuticals- gabapentin TAB 800MG	$550.0K	11
Palonosetron hydrochloride injection	$450.0K	9
Metoprolol succinate extended release	$432.5K	10
Pharmaceuticals zonisamide cap 100MG 100	$419.5K	9
Metoprolol succinate extended release	$405.6K	9
Pharmaceuticals-ondansetron odt 4MG	$400.0K	8
Pharmaceuticals gabapentin TAB 600MG 500	$350.0K	7
Pharmaceuticals- potassium cl er TAB	$300.5K	10
Pharmaceuticals- gabapentin TAB 800MG	$300.0K	6
Pharmaceuticals- ondansetron odt 4MG 1ud(BP)	$281.8K	9
Pharmaceutical medicine for human	$275.8K	12
Pharma drugs & medi bupropion TAB 300 MG	$269.6K	10

Amerisource Health Services imports 967 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Carvedilol	Cardiovascular	$4.0M	129	4.1%	7
2	Montelukast	Respiratory	$2.2M	44	1.3%	1
3	Fluconazole	Antifungals	$750.0K	28	0.8%	16
4	Glimepiride	Diabetes & Endocrine	$704.6K	38	0.9%	7
5	Etoposide	Oncology	$350.0K	7	3.2%	2
6	Anastrozole	Advanced Oncology	$338.7K	25	0.3%	11
7	Gemcitabine	Oncology	$300.0K	6	0.6%	11
8	Fulvestrant	Advanced Oncology	$250.0K	5	1.7%	11

Amerisource Health Services imports 8 pharmaceutical products across 6 categories into United States totaling $8.9M. The company is the #1 buyer for 1 product: Montelukast.

Amerisource Health Services — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Amerisource Health Services LLC is a U.S.-based healthcare distributor specializing in the importation and distribution of pharmaceutical products. The company operates primarily from its facility located at 2550 John Glenn Ave, Columbus, Ohio 43217. Established in 1986, Amerisource Health Services has been a key player in the pharmaceutical supply chain for over four decades.

The company focuses on importing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This strategic approach allows Amerisource Health Services to cater to the diverse needs of healthcare providers by ensuring a steady supply of ready-to-use medications. Their clientele includes hospitals, clinics, pharmacies, and other healthcare facilities across the United States.

2Distribution Network

Amerisource Health Services operates a centralized distribution center at its Columbus, Ohio location. This facility serves as the primary hub for receiving, storing, and dispatching pharmaceutical products. The strategic positioning of this center enables efficient logistics and timely delivery to various healthcare providers throughout the United States. While specific details about additional warehouse locations or international logistics capabilities are not publicly disclosed, the company's extensive import records indicate a robust and well-established distribution network.

3Industry Role

In the United States pharmaceutical supply chain, Amerisource Health Services functions as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company plays a crucial role in ensuring the availability of a wide range of medications to meet domestic healthcare demands. Their operations bridge the gap between international manufacturers and U.S. healthcare providers, facilitating access to essential pharmaceutical products.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Amerisource Health Services

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Amerisource Health Services demonstrates a significant concentration in its sourcing strategy, with a total import value of $8.9 million USD from India across 282 shipments. The company's portfolio is heavily concentrated, with the top five products accounting for 90% of the total import value. This concentration indicates a strategic focus on high-demand medications, which can lead to cost efficiencies and streamlined operations. However, such dependency also poses risks, including potential supply chain disruptions if any of these key suppliers face operational challenges. The shipment data reveals a stable relationship with Indian suppliers, as evidenced by the consistent import activity over the years. Nonetheless, diversifying the supplier base could mitigate risks associated with over-reliance on a limited number of suppliers.

2Supply Chain Resilience

Amerisource Health Services' supply chain resilience is supported by its diversified sourcing from 19 unique Indian suppliers, encompassing 967 unique formulations. This diversity in suppliers and product offerings enhances the company's ability to adapt to market changes and potential disruptions. While the primary shipping routes and regulatory compliance statuses of these suppliers are not detailed, the consistent import records suggest adherence to international shipping standards and regulatory requirements. To further bolster resilience, establishing relationships with additional backup suppliers and continuously monitoring the regulatory compliance of key partners would be prudent.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth the standards for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring that imported pharmaceuticals meet the required standards. For Indian generics to be marketed in the U.S., they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the brand-name counterpart.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent. Importers must register with the FDA and comply with the Drug Establishment Registration and Drug Listing requirements. Good Manufacturing Practice (GMP) certification is crucial; the FDA recognizes certifications from reputable authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized bodies to facilitate smooth importation processes. Additionally, wholesale distribution authorization is required, which involves meeting specific state and federal regulations governing the distribution of pharmaceutical products.

Amerisource Health Services — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Amerisource Health Services' product category focus on cardiovascular, respiratory, and antifungal medications aligns with prevalent health concerns in the United States. The dominance of cardiovascular diseases, respiratory conditions, and fungal infections in the U.S. population drives the demand for these therapeutic areas. By concentrating on these categories, the company ensures a steady supply of essential medications, meeting critical healthcare needs and positioning itself as a reliable partner for healthcare providers.

2Sourcing Profile

Amerisource Health Services employs a strategic sourcing approach, focusing on high-demand generic drugs from a diverse set of Indian suppliers. This strategy allows the company to offer a broad range of formulations, catering to various therapeutic areas. India's robust pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred sourcing destination. The company's sourcing profile reflects a commitment to quality, reliability, and cost-effectiveness in its procurement processes.

3Market Positioning

Seller's Guide — How to Become a Supplier to Amerisource Health Services

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Amerisource Health Services, especially those offering high-quality generic drugs in the cardiovascular, respiratory, and antifungal categories. Gaps in the company's current sourcing may exist in emerging therapeutic areas or specific formulations not currently in its portfolio. Indian exporters can capitalize on these opportunities by ensuring compliance with FDA regulations, obtaining necessary certifications, and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters aiming to supply Amerisource Health Services and the U.S. market must obtain FDA approval for their products, which involves submitting an ANDA for generics. They must hold valid GMP certifications from recognized authorities such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with U.S. labeling requirements, including English language labeling and serialization mandates, is essential. Establishing a reliable supply chain and ensuring consistent product quality are critical to meet the expectations of U.S. importers.

3How to Approach

Frequently Asked Questions — Amerisource Health Services

What products does Amerisource Health Services import from India?

Amerisource Health Services imports 8 pharmaceutical products across 6 categories. Top imports: Carvedilol ($4.0M), Montelukast ($2.2M), Fluconazole ($750.0K), Glimepiride ($704.6K), Etoposide ($350.0K).

Who supplies pharmaceuticals to Amerisource Health Services from India?

Amerisource Health Services sources from 19 verified Indian suppliers. The primary supplier is Glenmark Pharmaceuticals Limited (28.6% of imports, $12.8M).

What is Amerisource Health Services's total pharmaceutical import value?

Amerisource Health Services's total pharmaceutical import value from India is $8.9M, based on 282 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Amerisource Health Services focus on?

Amerisource Health Services imports across 6 categories. The largest: Cardiovascular (44.9%), Respiratory (24.8%), Antifungals (8.4%).

Get Full Amerisource Health Services Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.